



Biotechnologies Applied in Vaccine Research

Guest Editor:

Dr. Yuan-Chuan Chen

Department of Nursing and
Department of Medical
Technology, Jenteh Junior
College of Medicine, Nursing and
Management, Miaoli County
35664, Taiwan

Deadline for manuscript
submissions:

20 November 2024

Message from the Guest Editor

Dear Colleagues,

Traditional vaccines can be classified as inactivated vaccines, live attenuated vaccines, and subunit vaccines given orally, via intramuscular (IM) injection, and via subcutaneous (SC) injection. Recently, recombinant protein vaccines, DNA vaccines, mRNA vaccines, and multiple/alternative administration route vaccines have been developed for human use to make vaccines more secure and effective. These vaccine platforms have been developed using various biotechnologies, such as adenovirus vectors, nanoparticles, mRNA, recombination DNA, and other vaccine delivery systems.

In this Special Issue, we are inviting contributions related to advances in biotechnologies applied in vaccine research. It will explore the biotechnologies applied in the development of vaccine research and platforms. We welcome original research articles and reviews. Research areas may include vaccines, biotechnology, vaccine vectors, DNA, mRNA, subunits, novel adjuvants, and delivery systems. We look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com